These included two patients treated with trastuzumab deruxtecan for HER2‐positive (IHC 3+) metastatic colorectal and salivary gland cancers; one patient treated with trastuzumab plus pertuzumab for HER2‐positive (IHC 3+) metastatic colorectal cancer; one patient treated with pembrolizumab for TMB‐H (11.8 mutations/Mb) metastatic colorectal cancer; and one patient treated with alpelisib for PIK3CA‐mutated metastatic colorectal cancer. Here, PIK3CA is linked to salivary gland cancer.